STAT Plus: Cel-Sci is publicly upbeat about its cancer drug. Privately it’s trying to sell stock
Cel-Sci (CVM) chief executive Geert Kersten used a public letter to shareholders Thursday to express confidence in the outcome of an ongoing Phase 3 clinical trial involving its cancer immunotherapy.
Privately, Cel-Sci pitched a sale of its stock to institutional investors earlier this week, according to a source familiar with the deal. The proposed equity financing was aborted, but suggests Cel-Sci is more fearful about the future of the therapy, called Multikine, than it’s willing to say publicly.
